Pharmaceuticals

1. Nature, products and economic significance

Pharmaceutical manufacturing includes bulk drugs, finished medicines, vaccines, biological products and associated research services. It is a knowledge-intensive industry, but different segments have different locational requirements. Bulk-drug plants resemble specialised chemical factories and need reliable utilities, chemical inputs and effluent treatment. Formulation plants manufacture tablets, capsules, injections, creams and other dosage forms. Biotechnology-based production requires specialised laboratories, controlled environments and stringent biological quality assurance.

An active pharmaceutical ingredient produces the intended therapeutic effect. Excipients are other ingredients used for functions such as binding, preservation or delivery. Key starting materials and drug intermediates occur upstream in the manufacturing chain. Therefore, a country may export large quantities of finished medicines while depending on imports for selected APIs or their precursors. This distinction is central to understanding India’s pharmaceutical trade and strategic vulnerabilities.

Generic medicines contain the same active ingredient as the reference medicine and must meet applicable standards of quality, safety and efficacy. They are not synonymous with counterfeit or substandard drugs. Indian firms also sell branded generics, meaning generic medicines marketed under proprietary brand names. Vaccines and biosimilars are important additional segments; a biosimilar is highly similar to an approved reference biological product, rather than simply a chemically identical generic.

The sector supports skilled employment, exports, public-health programmes and affordable treatment abroad. India is widely called the pharmacy of the world because of its extensive supply of generic medicines and vaccines. However, production volume should not be confused with market value: patented innovative medicines often command much higher prices than high-volume generics.

2. Industrial geography and location factors

Pharmaceutical production is concentrated in western and southern India, with additional clusters in the Himalayan foothills and other regions. These concentrations reflect cumulative advantages: entrepreneurial networks, established chemical industries, pharmacy and engineering institutions, research laboratories, finance and skilled workers. Agglomeration allows firms to share specialised suppliers, testing services, machinery maintenance and logistics providers. Unlike iron and steel, pharmaceutical location cannot be explained primarily by proximity to heavy mineral deposits.

Gujarat’s Ahmedabad, Vadodara, Bharuch–Ankleshwar and Vapi belt benefits from a strong chemical and petrochemical base, industrial estates and access to western ports. Maharashtra combines corporate headquarters, finance and research in the Mumbai region with manufacturing around Pune, Thane and other centres. Hyderabad is a major bulk-drug, formulation and biotechnology centre. Its surrounding industrial areas and Genome Valley illustrate the interaction of manufacturing capabilities, research institutions and specialised infrastructure.

Bengaluru has strengths in biotechnology, research and biopharmaceutical services. Chennai and neighbouring areas support pharmaceutical and medical-product manufacturing, while Visakhapatnam has an important pharmaceutical industrial base, including Jawaharlal Nehru Pharma City at Parawada. Northern manufacturing centres include Baddi–Barotiwala–Nalagarh in Himachal Pradesh and Haridwar and nearby locations in Uttarakhand. Sikkim also hosts pharmaceutical manufacturing. Fiscal incentives and industrial policy helped attract investment to several Himalayan states.

Transport needs differ by product. High-value, low-weight and time-sensitive medicines can justify air freight, while sea transport carries substantial commercial consignments. Vaccines and some biological products require validated cold chains, though storage temperatures are product-specific. Reliable electricity, purified water, warehousing and temperature monitoring are crucial. Population size and disease patterns influence market demand, but manufacturing does not necessarily concentrate in the most populous states.

3. Historical development, regulation and intellectual property

Public-sector investment, scientific institutions and domestic entrepreneurship supported the development of Indian pharmaceutical capabilities after independence. The Patents Act, 1970, which came into force in 1972, excluded product patents for medicines while permitting process patents. This encouraged domestic firms to develop alternative manufacturing processes. The 2005 amendment restored pharmaceutical product patents as part of India’s compliance with the World Trade Organization’s Agreement on Trade-Related Aspects of Intellectual Property Rights, or TRIPS.

Patent protection and drug approval are separate legal matters. A patent concerns intellectual property; regulatory approval concerns whether a medicine may be manufactured or marketed under applicable requirements. Section 3(d) of the Patents Act restricts patenting of certain new forms of known substances unless the statutory efficacy requirement is satisfied. Compulsory licensing is another safeguard available under specified legal conditions; it does not amount to a general abolition of patents.

The Drugs and Cosmetics Act, 1940, and associated rules provide a foundational regulatory framework. The Central Drugs Standard Control Organisation, headed by the Drugs Controller General of India, performs central functions including new-drug approval and oversight of imported drugs. State licensing authorities handle important manufacturing and sale responsibilities. Regulation is therefore shared between central and state institutions rather than exercised exclusively by one national agency.

The National Pharmaceutical Pricing Authority administers price-control functions under the Drugs (Prices Control) Order, 2013, including ceiling prices for scheduled formulations. The National List of Essential Medicines informs the scheduled-medicine framework. Price control, generic substitution, public procurement and subsidised retail access are different policy instruments. Janaushadhi outlets improve access to affordable generic medicines, but the programme itself is neither a manufacturing subsidy nor the drug-approval authority.

4. Supply-chain security, policies and environmental concerns

India’s export strength coexists with substantial dependence on imported inputs, particularly from China, for several critical bulk drugs and intermediates. Dependence varies across products and should not be reduced to a single percentage for the entire industry. Pandemic-era disruptions highlighted risks from concentrated sourcing, transport interruptions and sudden changes in global demand. Diversification, domestic production and commercially viable inventories can improve resilience.

The Production Linked Incentive scheme for critical key starting materials, drug intermediates and APIs supports domestic manufacturing in selected product categories. A separate PLI scheme for pharmaceuticals covers specified higher-value product groups. The Scheme for Promotion of Bulk Drug Parks supports common infrastructure; parks in Gujarat, Himachal Pradesh and Andhra Pradesh were approved under it in 2022. A bulk-drug park, a PLI incentive and a state pharmaceutical cluster are related but distinct policy concepts.

Bulk-drug production can generate solvent residues, chemically complex wastewater and hazardous waste. Antibiotic residues in poorly treated effluent may contribute to the selection of antimicrobial resistance in the environment. Common effluent treatment plants, solvent recovery, segregation of waste streams and effective monitoring are therefore important. A common treatment facility is not automatically capable of removing every pharmaceutical pollutant.

Long-term competitiveness requires stronger quality assurance, research, regulatory compliance and sustainable production, not only low costs. Export-oriented plants must meet destination-market requirements as well as Indian law. Product recalls or quality failures can affect health, trade and trust. Industrial expansion must consequently balance affordable medicines, innovation, supply security, water availability and environmental protection.

Previous year questions

No UPSC question has been asked directly on this micro-topic yet. Use the practice questions below.

Practice questions